Genitourinary Cancers

The FDA has greenlit an investigation new drug application to expand the ongoing phase 1/2 ABILITY trial, which is evaluating the beta-only IL-2 superagonist MDNA11 in patients with solid tumors, to clinical trial sites in the United States.

Dr. Tagawa discusses the incidence and identification of FGFR alterations in bladder cancer, the approval and use of erdafitinib in the second-line setting for patients with advanced bladder cancer, and research directions with the FGFR inhibitor in the field.

Sesen Bio met with the FDA to discuss questions related to the Chemistry, Manufacturing, and Controls that were raised in the complete response letter previously issued by the regulatory agency regarding the biologics license application for Vicineum as a potential treatment for patients with Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer.

Phillip Palmbos, MD, PhD, discusses updates and therapeutic recommendations for the frontline treatment of patients with bladder cancer.

Sequential radiotherapy demonstrated preliminary efficacy and safety as a potential alternative to systemic therapy in patients with oligometastatic renal cell carcinoma.

Sarah Elizabeth Yentz, MD, discusses navigating frontline treatment selection in renal cell carcinoma.

Ziad Bakouny, MD, MSc, discusses recent ongoing research into the genomic drivers and biology of tRCC that could lead to improved outcomes for patients.

We spotlight key data presented during the 2021 ESMO Congress in kidney cancer, prostate cancer, and bladder cancer.

Jonathan A. Chatzkel, MD, discusses updates in first-line treatment options for metastatic urothelial cancer, as well as recommended treatments for patients with previously treated, locally advanced or metastatic urothelial cancer, and also newly diagnosed metastatic renal cell carcinoma.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion regarding approval of the combination of pembrolizumab and lenvatinib for 2 indications: select patients with renal cell carcinoma and select patients with endometrial carcinoma.

Toni Choueiri, MD, discusses key highlights from the 2021 Kidney Cancer Research Summit and exciting research efforts underway in renal cell carcinoma.

Pavlos Msaouel, MD, PhD, discusses how exercise can influence risk for patients with sickle cell trait to develop renal medullary carcinoma.

Eric Jonasch, MD, discusses recent pivotal developments in treating patients with renal cell carcinoma.

Efforts to move beyond chemotherapy alone for patients with advanced urothelial cancer, shift effective treatments into the curative setting in renal cell carcinoma, and effectively escalate treatment for patients with high-risk and high-volume prostate cancer have been successfully met.

Tian Zhang, MD, discusses the ongoing phase 3 PDIGREE trial, evaluating the combination ipilimumab plus nivolumab, followed by nivolumab with or without cabozantinib, in patients with advanced renal cell cancer.

Kevin Zarrabi, MD, discusses an analysis of real-world outcomes with axitinib plus pembrolizumab vs ipilimumab plus nivolumab in patients with metastatic clear cell renal cell carcinoma.

Neeraj Agarwal, MD, discusses the adverse effects associated with belzutifan in patients with renal cell carcinoma.

Robert J. Motzer, MD, spoke about the “exceptional” efficacy of the combination and how it fits into the evolving RCC treatment landscape.

Rohit Jain, MD, MPH, discusses the data from the phase 3 JAVELIN Bladder 100 trial examining avelumab as maintenance therapy following response or stable disease with first-line platinum-based chemotherapy in patients with advanced or metastatic urothelial cancer.

Treatment of metastatic renal cell carcinoma continues to evolve as new regimens steadily receive FDA approval and are added to the armamentarium.

Rohit Jain, MD, MPH, discusses the nuances of treatment selection for patients with platinum-eligible vs -ineligible metastatic urothelial carcinoma, the current state of immunotherapy in this disease, and factors to consider during the decision-making process in RCC and mCRPC.

The Japanese Ministry of Health, Labour, and Welfare has approved enfortumab vedotin for the treatment of patients with unresectable urothelial carcinoma that has progressed following chemotherapy.

Similarities in clinical characteristics in these patients despite differences in other genomic alterations may impact potential clinical trial treatment selection.

Patients with renal cell carcinoma and their families may have a lack of understanding about the disease, clinical trials, and psychosocial impact.

Frontline immunotherapy resulted in improved progression-free survival and overall survival compared with sunitinib in patients with advanced renal cell carcinoma; however, determining the benefit in those with favorable-risk disease must be examined further.